Skip to main content
. 2024 Jul 4;29(7):10.1111/adb.13421. doi: 10.1111/adb.13421

FIGURE 1.

FIGURE 1

Mitigating effects of the HDAC inhibitors, CB1 agonist, or TRPV1 antagonist against anxiety‐like behaviours. The parameter values of the EPM test (percentages of entries into open arms and time spent on open arms) at the 2‐h time point after the last NC (0.8 mg/kg, sc) and/or IM (10 min) treatment are shown as means with standard deviation (SD) bars (n = 10) for each HDAC inhibitor (SB or VA), CB1 agonist (AC), or TRPV1 antagonist (CZ) cotreatment group (with each ip dose [mg/kg]), and statistical significance in posthoc tests is denoted using the symbols as defined below. The detailed data and statistical results have been included in Table S1. (A) SB (100 mg/kg, ip) cotreatment groups (SB groups); (B) VA (300 mg/kg, ip) cotreatment groups (VA groups); (C) AC (0.2 mg/kg, ip) cotreatment groups (AC groups); (D) CZ (1 mg/kg, ip) cotreatment groups (CZ groups). **P < 0.01: significant attenuation as compared with the control group; ++P < 0.01: significant increase as compared with the NC, IM, or NC‐IM group without any cotreatments; $$P < 0.01: significant attenuation as compared with the IM group without any cotreatments.